Structural Heart Devices Market Summary

The global structural heart devices market size was estimated at USD 16.13 billion in 2024 and is projected to reach USD 50.99 billion by 2033, growing at a CAGR of 13.5% from 2025 to 2033. The rapid growth of the market is primarily driven by the increasing incidence of valvular heart diseases, along with the growing adoption of advanced minimally invasive procedures. Rising awareness regarding early detection and treatment of heart valve disorders, coupled with technological advancements in cardiac devices, is enhancing patient outcomes and driving the overall demand for structural heart devices worldwide.

According to an Oxford Academic article published in January 2025, the global age-standardized prevalence of cardiovascular disease stands at approximately 7,179 cases per 100,000 individuals, reflecting the significant global burden of cardiac conditions. This increasing prevalence underscores the need for timely medical interventions and innovative treatment approaches. Structural heart devices play a vital role in managing valvular and congenital heart diseases by restoring normal cardiac function and improving patient survival rates. The growing focus on early diagnosis, patient-centric treatment, and personalized cardiac care is propelling the adoption of advanced technologies such as transcatheter valves, occluders, and septal closure devices. These innovations are reducing the dependence on traditional open-heart surgeries and promoting faster recovery times.

Key Market Trends & Insights

  • The North America structural heart devices market dominated the global market in 2024, accounting for the largest revenue share of 52.5%. The region’s dominance is attributed to a high prevalence of cardiovascular diseases, a well-established healthcare infrastructure, and the availability of advanced diagnostic and treatment facilities. Increasing approval of new devices by regulatory authorities and growing adoption of minimally invasive procedures among patients are further driving market growth in the region.
  • The Canada structural heart devices market is anticipated to register the fastest growth rate during the forecast period. This growth is supported by increasing healthcare spending, improved access to advanced medical technologies, and rising awareness of cardiovascular disease management. Favorable government initiatives and investments in modern healthcare infrastructure are also contributing to the expanding adoption of structural heart therapies in the country.
  • In terms of type, the TAVR (Transcatheter Aortic Valve Replacement) segment held the largest revenue share in 2024. The segment’s dominance is driven by the rising prevalence of aortic stenosis and the increasing preference for minimally invasive valve replacement procedures. TAVR technology has gained widespread acceptance due to its proven clinical outcomes, shorter hospital stays, and suitability for high-risk and elderly patients who are not ideal candidates for traditional surgery.

Order a free sample PDF of the Structural Heart Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

  • 2024 Market Size: USD 16.13 Billion
  • 2033 Projected Market Size: USD 50.99 Billion
  • CAGR (2025-2033): 13.5%
  • North America: Largest market in 2024
  • Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Key structural heart devices industry participants focus on devising innovative business growth strategies, such as expanding their product portfolios, partnerships and collaborations, mergers and acquisitions, and business footprints.

Key Players

  • Boston Scientific Corporation
  • Medtronic
  • Edwards Lifesciences Corporation
  • Abbott Laboratories
  • JUDE MEDICAL
  • Biomerics
  • Comed BV
  • LivaNova PLC
  • JenaValve Technology, Inc.
  • CardioKinetix

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global structural heart devices market is expected to experience robust growth over the coming years, driven by rising cardiovascular disease prevalence, technological innovation, and growing preference for minimally invasive treatments. The increasing use of devices such as TAVR and septal closure systems is transforming cardiac care by offering safer and more effective alternatives to open-heart surgery. North America remains a key market, while emerging economies present significant opportunities due to expanding healthcare infrastructure and patient awareness. Continuous advancements in materials, device design, and imaging technologies will further enhance treatment precision, improving patient outcomes and shaping the market’s future trajectory.